Ticker

Analyst Price Targets — HALO

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
June 3, 2026 1:02 pmUBS$90.00$68.78StreetInsider Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential
May 12, 2026 12:05 pmMorgan Stanley$93.00$71.11TheFly Halozyme price target lowered to $93 from $96 at Morgan Stanley
April 29, 2026 10:10 amMitchell KapoorH.C. Wainwright$95.00$63.86TheFly Halozyme price target raised to $95 from $90 at H.C. Wainwright
April 21, 2026 12:43 pmMorgan Stanley$96.00$69.57TheFly Halozyme price target raised to $96 from $94 at Morgan Stanley
February 19, 2026 1:43 pmMorgan Stanley$94.00$72.19TheFly Halozyme price target raised to $94 from $78 at Morgan Stanley
February 19, 2026 11:28 amWells Fargo$75.00$73.23TheFly Halozyme price target raised to $75 from $65 at Wells Fargo
January 8, 2026 12:39 pmMorgan Stanley$75.00$75.11TheFly Halozyme price target lowered to $75 from $79 at Morgan Stanley
December 4, 2025 11:55 amUBS$56.00$64.66TheFly Halozyme downgraded to Sell from Neutral at Goldman Sachs
December 4, 2025 11:51 amCorinne JenkinsGoldman Sachs$56.00$62.82StreetInsider Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'
November 4, 2025 10:43 amJMP Securities$92.00$66.20TheFly Halozyme price target raised to $92 from $91 at Citizens JMP

Latest News for HALO

Time for HALO Sectors & ETFs?

HALO stocks are gaining favor as investors rotate toward tangible assets and AI-resistant businesses. Here are ETFs to play the trend.

Zacks Investment Research • Jul 16, 2026
Time to Buy Wide Moat & HALO ETFs?

Wall Street is caught in the midst of shifting geopolitical stances of the United States and Iran, chances of higher global inflation, weak U.S. jobs data, the possibility of stagflation in the U.S. economy, and the Fed's likely dilemma in fixing the monetary policy amid a weakening labor market and accelerating inflation. Also, the occasional selloffs in the red-hot artificial intelligence (AI) space have been a…

Zacks Investment Research • Jul 10, 2026
Halozyme Appoints David Ramsay as President Drug Delivery

SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created role, Mr.

PRNewsWire • Jun 30, 2026
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029

SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on June 12, 2026. "Based on our analysis of CMS's…

PRNewsWire • Jun 15, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

Senate Trading Disclosures

NameTransaction DateTypeAssetAmountLink

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top